Robin Vora, MD
Ophthalmology · Oakland, CANPI 1700964384
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Astellas Pharma US Inc at 47.8% of the total. 2025 is the largest year on record at $76,090, more than ten times the $43 reported in 2019. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $868.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$67K
- Regeneron Healthcare Solutions, Inc.$42K
- Regeneron$15K
- Genentech USA, Inc.$8K
- Apellis Pharmaceuticals, Inc.$4K
- Eyepoint US, Inc.$3K
- plus $2K from 8 others
Across 32 payments — averaging $4627.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$148K
What the payments were for
- Consulting fees$39,86028%
- Speaking & faculty fees$81,04258%
- Travel & lodging$13,92810%
- Food & beverage$5,9174%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 54 | $67,296 |
| Regeneron Healthcare Solutions, Inc. | 32 | $42,396 |
| Regeneron | 25 | $14,548 |
| Genentech USA, Inc. | 11 | $8,328 |
| Apellis Pharmaceuticals, Inc. | 7 | $3,666 |
| Eyepoint US, Inc. | 5 | $2,536 |
| Ocular Therapeutix, Inc. | 13 | $1,097 |
| Alcon | 6 | $377 |
| Neurotech Pharmaceuticals, Inc. | 3 | $205 |
| Harrow Eye, LLC | 1 | $104 |
| Biomerieux Inc | 1 | $90 |
| Astellas Pharma Global Development | 2 | $62 |
| Carl Zeiss Meditec, Inc. | 1 | $30 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$140,746 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cyclosporine | 19 | $2,085 |
| Prednisolone Acetate | 16 | $961 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 53 | $957 |
| Latanoprost | 31 | $420 |
| Timolol Maleate | 11 | $187 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Oakland
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.